Ablation of galectin-3 induces p27 KIP1-dependent premature senescence without oncogenic stress

Cell Death and Differentiation

Volumn 21, Issue 11, 2014, Pages 1769-1779

  Kim, S J ^a,b   Lee, H W ^a,b   Gu Kang, H ^a,b   La, S H ^a,b   Choi, Il Ju ^c   Ro, J Y ^d   Bresalier, R S ^e   Song, J ^b   Chun, K H ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

^c National Cancer Center   (South Korea)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1B; GALECTIN 3; RETINOBLASTOMA PROTEIN; S PHASE KINASE ASSOCIATED PROTEIN;

ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOGENESIS; CELL AGING; GENETICS; HUMAN; METABOLISM; MOUSE; ONCOGENE; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; CARCINOGENESIS; CELL AGING; CELL LINE, TUMOR; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASE INHIBITOR PROTEINS; CYCLIN-DEPENDENT KINASES; GALECTIN 3; HUMANS; MICE; ONCOGENES; RETINOBLASTOMA PROTEIN; S-PHASE KINASE-ASSOCIATED PROTEINS;

EID: 84927130827     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2014.88     Document Type: Article

References (45)

1. Larsson LG. Oncogene-and tumor suppressor gene-mediated suppression of cellular senescence. Semin Cancer Biol 2011; 21: 367-376.
2. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature 2004; 432: 307-315.
3. Kuilman T, Michaloglou C, Mooi WJ, Peeper DS. The essence of senescence. Genes Dev 2010; 24: 2463-2479.
4. Chandler H, Peters G. Stressing the cell cycle in senescence and aging. Curr Opin Cell Biol 2013; 25: 765-771.
5. Kim SJ, Choi IJ, Cheong TC, Lee SJ, Lotan R, Park SH et al. Galectin-3 increases gastric cancer cell motility by up-regulating fascin-1 expression. Gastroenterology 2010; 138: 1035-1045.
6. Kim SJ, Shin JY, Lee KD, Bae YK, Choi IJ, Park SH et al. Galectin-3 facilitates cell motility in gastric cancer by up-regulating protease-activated receptor-1 (PAR-1) and matrix metalloproteinase-1 (MMP-1). PLoS One 2011; 6: e25103.
7. Wang YG, Kim SJ, Baek JH, Lee HW, Jeong SY, Chun KH. Galectin-3 increases the motility of mouse melanoma cells by regulating matrix metalloproteinase-1 expression. Exp Mol Med 2012; 44: 387-393.
8. Dumic J, Dabelic S, Flogel M. Galectin-3: an open-ended story. Biochim Biophys Acta 2006; 1760: 616-635.
9. Nakahara S, Raz A. Regulation of cancer-related gene expression by galectin-3 and the molecular mechanism of its nuclear import pathway. Cancer Metastasis Rev 2007; 26: 605-610.
10. Kim SJ, Choi IJ, Cheong TC, Lee SJ, Lotan R, Park SH et al. Galectin-3 increases gastric cancer cell motility by up-regulating fascin-1 expression. Gastroenterology 2010; 138: 1035-1045, e1031-1032.
11. Hershko DD, Shapira M. Prognostic role of p27Kip1 deregulation in colorectal cancer. Cancer 2006; 107: 668-675.
12. Lloyd RV, Erickson LA, Jin L, Kulig E, Qian X, Cheville JC et al. p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 1999; 154: 313-323.
13. Barbareschi M. p27 Expression, a cyclin dependent kinase inhibitor in breast carcinoma. Adv Clin Path 1999; 3: 119-127.
14. Mamillapalli R, Gavrilova N, Mihaylova VT, Tsvetkov LM, Wu H, Zhang H et al. PTEN regulates the ubiquitin-dependent degradation of the CDK inhibitor p27(KIP1) through the ubiquitin E3 ligase SCF(SKP2). Curr Biol 2001; 11: 263-267.
15. Zhang L, Wang C. F-box protein Skp2: a novel transcriptional target of E2F. Oncogene 2006; 25: 2615-2627.
16. Hershko DD. Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer. Cancer 2008; 112: 1415-1424.
17. Masuda TA, Inoue H, Sonoda H, Mine S, Yoshikawa Y, Nakayama K et al. Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis. Cancer Res 2002; 62: 3819-3825.
18. Lin HK, Chen Z, Wang G, Nardella C, Lee SW, Chan CH et al. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 2010; 464: 374-379.
19. Bringold F, Serrano M. Tumor suppressors and oncogenes in cellular senescence. Exp Gerontol 2000; 35: 317-329.
20. Rayess H, Wang MB, Srivatsan ES. Cellular senescence and tumor suppressor gene p16. Int J Cancer 2012; 130: 1715-1725.
21. Ko A, Shin JY, Seo J, Lee KD, Lee EW, Lee MS et al. Acceleration of gastric tumorigenesis through MKRN1-mediated posttranslational regulation of p14ARF. J Natl Cancer Inst 2012; 104: 1660-1672.
22. Cheong TC, Shin JY, Chun KH. Silencing of galectin-3 changes the gene expression and augments the sensitivity of gastric cancer cells to chemotherapeutic agents. Cancer Sci 2010; 101: 94-102.
23. Song S, Ji B, Ramachandran V, Wang H, Hafley M, Logsdon C et al. Overexpressed galectin-3 in pancreatic cancer induces cell proliferation and invasion by binding Ras and activating Ras signaling. PLoS One 2012; 7: e42699.
24. Kim SJ, Shin JY, Cheong TC, Choi IJ, Lee YS, Park SH et al. Galectin-3 germline variant at position 191 enhances nuclear accumulation and activation of beta-catenin in gastric cancer. Clin Exp Metastasis 2011; 28: 743-750.
25. Oka N, Nakahara S, Takenaka Y, Fukumori T, Hogan V, Kanayama HO et al. Galectin-3 inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by activating Akt in human bladder carcinoma cells. Cancer Res 2005; 65: 7546-7553.
26. Wang Y, Balan V, Kho D, Hogan V, Nangia-Makker P, Raz A. Galectin-3 regulates p21 stability in human prostate cancer cells. Oncogene 2013; 32: 5058-5065.
27. Giacinti C, Giordano A. RB and cell cycle progression. Oncogene 2006; 25: 5220-5227.
28. Chen T, Xue L, Niu J, Ma L, Li N, Cao X et al. The retinoblastoma protein selectively represses E2F1 targets via a TAAC DNA element during cellular senescence. J Biol Chem 2012; 287: 37540-37551.
29. Lin HM, Pestell RG, Raz A, Kim HR. Galectin-3 enhances cyclin D(1) promoter activity through SP1 and a cAMP-responsive element in human breast epithelial cells. Oncogene 2002; 21: 8001-8010.
30. Cito L, Pentimalli F, Forte I, Mattioli E, Giordano A. Rb family proteins in gastric cancer (review). Oncol Rep 2010; 24: 1411-1418.
31. Du W, Searle JS. The rb pathway and cancer therapeutics. Curr Drug Targets 2009; 10: 581-589.
32. Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer 2008; 8: 671-682.
33. Nitti D, Belluco C, Mammano E, Marchet A, Ambrosi A, Mencarelli R et al. Low level of p27(Kip1) protein expression in gastric adenocarcinoma is associated with disease progression and poor outcome. J Surg Oncol 2002; 81: 167-175; discussion 175-166.
34. Wiksten JP, Lundin J, Nordling S, Kokkola A, von Boguslawski K, Haglund C. The prognostic value of p27 in gastric cancer. Oncology 2002; 63: 180-184.
35. Kim HR, Lin HM, Biliran H, Raz A. Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Res 1999; 59: 4148-4154.
36. Ma XM, Liu Y, Guo JW, Liu JH, Zuo LF. Relation of overexpression of S phase kinaseassociated protein 2 with reduced expression of p27 and PTEN in human gastric carcinoma. World J Gastroenterol 2005; 11: 6716-6721.
37. Wang G, Chan CH, Gao Y, Lin HK. Novel roles of Skp2 E3 ligase in cellular senescence, cancer progression, and metastasis. Chin J Cancer 2012; 31: 169-177.
38. Hsu DK, Yang RY, Pan Z, Yu L, Salomon DR, Fung-Leung WP et al. Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. Am J Pathol 2000; 156: 1073-1083.
39. Kim JH, Park KW, Lee EW, Jang WS, Seo J, Shin S et al. Suppression of PPARgamma through MKRN1-mediated ubiquitination and degradation prevents adipocyte differentiation. Cell Death Differ 2014; 21: 594-603.
40. Kim SJ, Shin JY, Lee KD, Bae YK, Sung KW, Nam SJ et al. MicroRNA let-7a suppresses breast cancer cell migration and invasion through downregulation of C-C chemokine receptor type 7. Breast Cancer Res 2012; 14: R14.
41. Lee MS, Seo J, Choi DY, Lee EW, Ko A, Ha NC et al. Stabilization of p21 (Cip1/WAF1) following Tip60-dependent acetylation is required for p21-mediated DNA damage response. Cell Death Differ 2013; 20: 620-629.
42. Kim SJ, Oh JS, Shin JY, Lee KD, Sung KW, Nam SJ et al. Development of microRNA-145 for therapeutic application in breast cancer. J Control Release 2011; 155: 427-434.
43. Ahn YH, Yi H, Shin JY, Lee KD, Shin SP, Lee SJ et al. STAT3 silencing enhances the efficacy of the HSV.tk suicide gene in gastrointestinal cancer therapy. Clin Exp Metastasis 2012; 29: 359-369.
44. Lee SA, Choi SR, Jang JS, Lee JH, Roh MH, Kim SO et al. Expression of VEGF, EGFR, and IL-6 in gastric adenomas and adenocarcinomas by endoscopic submucosal dissection. Dig Dis Sci 2010; 55: 1955-1963.
45. Kim SJ, Hwang JA, Ro JY, Lee YS, Chun KH. Galectin-7 is epigenetically-regulated tumor suppressor in gastric cancer. Oncotarget 2013; 4: 1461-1471.